In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 0.02 below Aditxt Inc average.

Within Major Pharmaceutical Preparations industry 528 other companies have achieved higher Quick Ratio than Aditxt Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from to 5090.

Explain Quick Ratio?
How much Cash & cash equivalents ADTX�s has?
What are ADTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ADTX Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	4 %	-52.27 %	-26.4 %	-22.51 %	-36.36 %
Y / Y Cash & cash equivalent Change	-46.42 %	291.15 %	-53.97 %	254.84 %	466.02 %
Quick Ratio MRQ	0.02	0.34	0.01	0.02	0.05
ADTX's Total Ranking	# 5090	#	#	#	#
Seq. Current Liabilities Change	15.65 %	-41.94 %	7.02 %	44.72 %	-46.92 %
Seq. Cash & cash equivalent Change	-91.99 %	1960.12 %	-49.64 %	-35.51 %	-41.54 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 529
Healthcare Sector	# 1080
Overall Market	# 5090

Quick Ratio Statistics
High	Average	Low
62.27	5.14	0
(Sep 30 2020)		(Dec 31 2019)

Financial Statements
Aditxt Inc 's Current Liabilities	$ 11 Millions	Visit ADTX's Balance sheet
Aditxt Inc 's Cash & cash equivalent	$ 0 Millions	Visit ADTX's Balance sheet
Source of ADTX's Sales		Visit ADTX's Sales by Geography

Cumulative Aditxt Inc 's Quick Ratio

ADTX's Quick Ratio for the trailling 12 Months

ADTX Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-28.01 %	-34.09 %	-24.53 %	-4.06 %	19.75 %
Y / Y Cash & cash equivalent TTM Growth	127.81 %	212.14 %	192.68 %	5.7 %	-6.59 %
Quick Ratio TTM	0.08	0.08	0.03	0.03	0.02
Total Ranking TTM	# 4237	#	#	#	#
Seq. Current Liabilities TTM Growth	0.82 %	-16.75 %	-8.63 %	-6.13 %	-7.69 %
Seq. Cash & cash equivalent TTM Growth	-5.36 %	135.32 %	-9.38 %	12.87 %	29.68 %

Quick ratio ranking by company, industry and sector >> Back to ADTX Financial Strength Comparisons >> Go to Compare ADTX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the increase in Current Liabilities in the Q1 2026 to $11.45 millions, cumulative Quick Ratio remained unchanged at 0.08 below the Aditxt Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 507 other companies have achieved higher Quick Ratio than Aditxt Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from to 4237.

Explain Quick Ratio?
How much Cash & cash equivalents ADTX�s has?
What are ADTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 508
Healthcare Sector	# 1058
Within the Market	# 4237

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.42	0.47	0.02
(Mar 31 2022)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Hcw Biologics Inc	0.06	$ 1.229 Millions	$ 19.959 Millions
Os Therapies Incorporated	0.05	$ 0.918 Millions	$ 18.331 Millions
Citius Oncology Inc	0.04	$ 2.633 Millions	$ 58.812 Millions
Abvc Biopharma Inc	0.04	$ 0.203 Millions	$ 5.393 Millions
IMPACT BIOMEDICAL INC.	0.03	$ 0.020 Millions	$ 0.584 Millions
Provectus Biopharmaceuticals Inc	0.03	$ 0.224 Millions	$ 7.242 Millions
Evofem Biosciences Inc	0.03	$ 2.379 Millions	$ 78.752 Millions
Gridai Technologies Corp	0.02	$ 0.386 Millions	$ 16.232 Millions
Aditxt Inc	0.02	$ 0.269 Millions	$ 11.452 Millions
China Pharma Holdings Inc	0.02	$ 0.168 Millions	$ 7.268 Millions
Northwest Biotherapeutics Inc	0.02	$ 1.786 Millions	$ 82.973 Millions
Lakewood-Amedex Biotherapeutics Inc.	0.02	$ 0.012 Millions	$ 0.548 Millions
Zyversa Therapeutics Inc	0.02	$ 0.303 Millions	$ 14.739 Millions
Sunshine Biopharma Inc	0.01	$ 0.072 Millions	$ 5.878 Millions
Lftd Partners Inc	0.01	$ 0.054 Millions	$ 4.543 Millions
Semnur Pharmaceuticals Inc	0.01	$ 0.103 Millions	$ 10.380 Millions
Neonc Technologies Holdings Inc	0.01	$ 0.139 Millions	$ 16.288 Millions
Cnbx Pharmaceuticals Inc	0.00	$ 0.012 Millions	$ 2.548 Millions

Date modified: 2026-09-26T07:40:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.